These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


415 related items for PubMed ID: 24844252

  • 1. Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.
    Fu H, Ma C, Tang L, Wu F, Liu B, Wang H.
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):121-8. PubMed ID: 24844252
    [Abstract] [Full Text] [Related]

  • 2. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
    Ma C, Xie J, Liu W, Wang G, Zuo S, Wang X, Wu F.
    Cochrane Database Syst Rev; 2010 Nov 10; 2010(11):CD008302. PubMed ID: 21069705
    [Abstract] [Full Text] [Related]

  • 3. rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis.
    Ma C, Tang L, Fu H, Li J, Wang H.
    Nucl Med Commun; 2013 Dec 10; 34(12):1150-6. PubMed ID: 24025918
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
    Freudenberg LS, Frömke C, Petrich T, Marlowe RJ, Koska WW, Brandau W, Eising EG, Knust EJ, Bockisch A, Jentzen W.
    Exp Clin Endocrinol Diabetes; 2010 Jul 10; 118(7):393-9. PubMed ID: 19856257
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
    Campennì A, Amato E, Laudicella R, Alibrandi A, Cardile D, Pignata SA, Trimarchi F, Ruggeri RM, Auditore L, Baldari S.
    Endocrine; 2019 Jul 10; 65(1):132-137. PubMed ID: 30875058
    [Abstract] [Full Text] [Related]

  • 10. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer.
    Plyku D, Hobbs RF, Huang K, Atkins F, Garcia C, Sgouros G, Van Nostrand D.
    J Nucl Med; 2017 Jul 10; 58(7):1146-1154. PubMed ID: 28104741
    [Abstract] [Full Text] [Related]

  • 11. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.
    Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, Brandau W, Knapp WH, Bockisch A.
    Eur J Nucl Med Mol Imaging; 2010 Dec 10; 37(12):2267-76. PubMed ID: 20661558
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F, Mazzarotto R, Mian C, Lora O, Saladini G, Servodio O, Basso M, Pennelli G, Pelizzo MR, Sotti G.
    Clin Oncol (R Coll Radiol); 2012 Apr 10; 24(3):162-8. PubMed ID: 21411300
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods.
    Vallejo Casas JA, Mena Bares LM, Gálvez MA, Marlowe RJ, Latre Romero JM, Martínez-Paredes M.
    Nucl Med Commun; 2011 Sep 10; 32(9):840-6. PubMed ID: 21691237
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
    Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Mete M, Jonklaas J, Wartofsky L.
    Thyroid; 2012 Mar 10; 22(3):310-7. PubMed ID: 22313411
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 21.